



30 March 2021

Sydney, Australia

Notice of Ceasing to be a Substantial Holder

Sydney, 30 March 2021: Nyrada Inc (ASX: NYR), advises, further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depositary Interests ("CDIs"), a Notice of Ceasing to be a Substantial Holder in relation to Nyrada. Details of the change in CDIs ("Relevant Interests") are as follows:

Name of Substantial Holder of Relevant Interests: Eleanore Goodridge

Date of ceasing to be a Substantial Holder: 30 March 2021

Previous and present voting power of Substantial Holder (through CHES Depositary Nominees Pty Ltd):

Previous notice		Present notice	
Number of CDIs	Voting power	Number of CDIs	Voting Power
5,974,832	5.39%	5,474,832	3.95%

Present Relevant Interests:

Holder of Relevant Interest	Registered Holdings of CDIs	Relevant Interest Number of CDIs	Voting Power
Eleanore Goodridge	Goodridge Nominees Pty Ltd atf The Goodridge Family A/C	4,262,416 (1)	3.07%
Eleanore Goodridge	Goodridge Foundation Pty Ltd atf The Goodridge Foundation	1,212,416 (1)	0.88%

(1) includes 1,212,416 CDIs in each holding escrowed for 24 months from IPO

-ENDS-



About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by John Moore, Non-Executive Chairman

Investor & Corporate Enquiries:

Laura Vize
Investor Relations Manager
T: 0417 026 056
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com